Distinct white matter alteration patterns in post-infectious and gradual onset chronic fatigue syndrome revealed by diffusion MRI.
Yu, Qiang, Kwiatek, Richard A, Del Fante, Peter et al. · Scientific reports · 2025 · DOI
Quick Summary
This study used advanced brain imaging to examine whether two types of ME/CFS—one that starts suddenly after an infection and one that develops gradually—show different patterns of damage in the brain's white matter (the nerve fibers that allow brain regions to communicate). Researchers found that these two types of ME/CFS do indeed show distinct patterns, suggesting they may involve different disease processes. This finding supports the idea that ME/CFS is not a single uniform condition but may require different approaches depending on how it started.
Why It Matters
For decades, clinicians and researchers have debated whether post-infectious and gradual-onset ME/CFS represent different diseases or variants of the same condition. This study provides the first neurobiological evidence that these two presentations involve distinct white matter alterations, validating clinical suspicions and suggesting that patient stratification by onset type may be necessary for future treatment development and research. This finding could lead to more personalized diagnostic and therapeutic approaches.
Observed Findings
Post-infectious ME/CFS showed significantly higher axial diffusivity in association and projection fibers compared to healthy controls.
Higher axial diffusivity in PI-ME/CFS was significantly associated with worse self-reported physical health.
Gradual-onset ME/CFS exhibited significantly decreased axial diffusivity in the corpus callosum.
Lower axial diffusivity in GO-ME/CFS was associated with worse mental health outcomes in commissural and projection fibers.
No significant group differences were found for fractional anisotropy, mean diffusivity, or radial diffusivity across any groups.
Inferred Conclusions
Distinct patterns of axial diffusivity alterations in PI-ME/CFS and GO-ME/CFS provide neurophysiological evidence that these two presentations involve different underlying disease processes.
The differential association of white matter changes with physical versus mental health outcomes suggests that PI-ME/CFS and GO-ME/CFS may require distinct clinical and therapeutic approaches.
ME/CFS is a heterogeneous condition with biological subgroups that should be considered separately in future research and clinical practice.
Remaining Questions
Do white matter alterations precede symptom onset, or do they develop as a consequence of the disease process? Longitudinal studies from pre-symptomatic or early-stage patients would help answer this.
What This Study Does Not Prove
This study does not establish that white matter changes cause ME/CFS symptoms—it only shows they are associated with the condition. The cross-sectional design prevents determination of whether these white matter alterations are present before symptom onset, develop as a consequence of the disease, or result from deconditioning. Long-term follow-up studies would be needed to determine if these biomarkers predict disease progression or treatment response.
What specific pathophysiological mechanisms drive the different white matter changes in PI-ME/CFS versus GO-ME/CFS—such as neuroinflammation, viral persistence, or autonomous nervous system dysfunction?
Do these white matter biomarkers predict treatment response, disease progression, or recovery rates in either patient subgroup?
How do these white matter findings relate to other proposed ME/CFS biomarkers (immune dysfunction, mitochondrial impairment, autonomic abnormalities), and do they occur independently or in concert?